Th17 cells and IL-17 promote the skin and lung inflammation and fibrosis process in a bleomycin-induced murine model of systemic sclerosis

Clinical and Experimental Rheumatology

Volumn 34, Issue , 2016, Pages 14-22

  Lei, Ling ^a   Zhao, Cheng ^a   Qin, Fang ^a   He, Zhi Yi ^a   Wang, Xu ^a   Zhong, Xiao Ning ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Bleomycin; Fibroblast; Interleukin 17; Mice; Systemic sclerosis; Th17 cells

Indexed keywords

COLLAGEN; INTERLEUKIN 17; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA1; AUTACOID; BLEOMYCIN; IL17A PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DERMATITIS; DISEASE ASSOCIATION; FEMALE; LUNG FIBROBLAST; LUNG FIBROSIS; LUNG INFILTRATE; MOUSE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SKIN FIBROSIS; SKIN INFILTRATE; TH17 CELL; ANIMAL; BAGG ALBINO MOUSE; CELL CULTURE; CELL PROLIFERATION; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; FIBROBLAST; FIBROSIS; IMMUNOLOGY; LUNG; METABOLISM; PATHOLOGY; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; SKIN; SYSTEMIC SCLEROSIS;

ANIMALS; BLEOMYCIN; CELL PROLIFERATION; CELLS, CULTURED; COLLAGEN; DERMATITIS; DISEASE MODELS, ANIMAL; FEMALE; FIBROBLASTS; FIBROSIS; INFLAMMATION MEDIATORS; INTERLEUKIN-17; LUNG; MICE, INBRED BALB C; PNEUMONIA; PULMONARY FIBROSIS; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; SKIN; TH17 CELLS;

EID: 84994422946     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. JIMENEZ SA: Role of endothelial to mesenchymal transition in the pathogenesis of the vascular alterations in systemic sclerosis. ISRN Rheumatol 2013; 835948.
2. PERNIS AB: Th17 cells in rheumatoid arthritis and systemic lupus erythematosus. J Intern Med 2009; 65: 644-52.
3. MIOSSEC P, KORN T, KUCHROO VK: Interleukin-17 and type 17 helper T cells. N Engl J Med 2009; 361: 888-98.
4. KURASAWA K, HIROSE K, SANO H et al.: Increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum 2000; 43: 2455-63.
5. FENOGLIO D, BATTAGLIA F, PARODI A et al.: Alteration of Th17 and Treg cell subpopulations co-exist in patients affected with systemic sclerosis. Clin Immunol 2011; 139: 249-57.
6. RODRIGUEZ-REYNA TS, FURUZAWA-CARBALLEDA J, CABIEDES J et al.: Th17 peripheral cells are increased in diffuse cutaneous systemic sclerosis compared with limited illness: a cross-sectional study. Rheumatol Int 2012; 32: 2653-60.
7. LEI L, ZHONG XN, ZHAO C et al.: Expression and significance of Th17 cells and related cytokines in a murine model of systemic sclerosis. Beijing Da Xue Xue Bao 2012; 44: 259-64.
8. LEI L, ZHONG XN, HE ZY et al.: IL-21 Induction of CD4+ T Cell Differentiation into Th17 Cells Contributes to Bleomycin-Induced Fibrosis in Mice. Cell Biol Int 2015; 39: 388-99.
9. OKAMOTO Y, HASEGAWA M, MATSUSHITA T et al.: Potential roles of interleukin-17A in the development of skin fibrosis in mice. Arthritis Rheum 2012; 64: 3726-35.
10. NAKASHIMA T, JINNIN M, YAMANE K et al.: Impaired IL-17 signaling pathway contributes to the increased collagen expression in scleroderma fibroblasts. J Immunol 2012; 188: 3573-83.
11. YAMAMOTO T, TAKAGAWA S, KATAYAMA I et al.: Effect of superoxide dismutase on bleomycin-induced dermal sclerosis: implications for the treatment of systemic sclerosis. J Invest Dermatol 1999; 113: 843-7.
12. ISHIKAW AH, TAKEDA K, OKAMOTO A et al.: Induction of autoimmunity in a bleomycin induced murine model of experimental systemic sclerosis: an important role for CD4+ T cells. J Invest Dermatol 2009; 129: 1688-95.
13. FINESCHI S, BONGIOVANNI M, DONATI Y et al.: In vivo investigations on anti-fibrotic potential of proteasome inhibition in lung and skin fibrosis. Am J Respir Cell Mol Biol 2008; 39: 458-65.
14. ASHCROFT T, SIMPSON JM, TIMBERI V: Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol 1988; 41: 467-70.
15. ZHANG Y, McCORMICK LL, DESAI SR et al.: Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation. J Immunol 2002; 168: 3088-98.
16. D'HULST AI, VERMAELEN KY, BRUSSELLE GG et al.: Time course of cigarette smoke-induced pulmonary inflammation in mice. Eur Respir J 2005; 26: 204-13.
17. JU S, ZHANG D, WANG Y et al.: Correlation of the expression levels of BLyS and its receptors mRNA in patients with systemic lupus erythematosus. Clin Biochem 2006; 39: 1131-7.
18. YANG X, YANG J, XING X et al.: Increased frequency of Th17 cells in systemic sclerosis is related to disease activity and collagen overproduction. Arthritis Res Ther 2014; 16: R4.
19. TRUCHETET ME, BREMBILLA NC, MONTANARI E et al.: Increased frequency of circulating Th22 in addition to Th17 and Th2 lymphocytes insystemic sclerosis: association with interstitial lung disease. Arthritis Res Ther 2011; 13: R166.
20. BREMBILLA NC, MONTANARI E, TRUCHETET ME et al.: Th17 cells favor inflammatory responses while inhibiting type I collagen deposition by dermal fibroblasts: differential effects in healthy and systemic sclerosis fibroblasts. Arthritis Res Ther 2013; 15: R151.
21. TRUCHETET ME, BREMBILLA NC, MONTANARI E et al.: Interleukin-17A+ cell counts are increased in systemic sclerosis skin and their number is inversely correlated with the extent of skin involvement. Arthritis Rheum 2013; 65: 1347-56.
22. MURATA M, FUJIMOTO M, MATSUSHITA T et al.: Clinical association of serum interleukin-17 levels in systemic sclerosis: is systemic sclerosis a Th17 disease? J Dermatol Sci 2008; 50: 240-2.
23. PAPP G, HORATH IF, BARATH S et al.: Altered T-cell and regulatory cell repertoire in patients with diffuse cutaneous systemic sclerosis. Scand J Rheumatol 2011; 40: 205-10.
24. YOSHIZAKI A, YANABA K, IWATA Y et al.: Cell adhesion molecules regulate fibrotic process via Th1/Th2/Th17 cell balance in a bleomycin-induced scleroderma model. J Immunol 2010; 185: 2502-15.
25. WILSON MS, MADALA SK, RAMALINGAM TR et al.: Bleomycin and IL-1-mediated pulmonary fibrosis is IL-17A dependent. J Exp Med 2010; 207: 535-52.
26. MI S, LI Z, YANG HZ et al.: Blocking IL-17A promotes the resolution of pulmonary inflammation and fibrosis via TGF-1-dependent and-independent mechanisms. J Immunol 2011; 187: 3003-14.
27. GASSE P, RITEAU N, VACHER R et al.: IL-1 and IL-23 mediate early IL-17A production in pulmo nary inflammation leading to late fibrosis. PLoS One 2011; 6: e23185.
28. BARSOTTI S, BELLANDO RANDONE S et al.: Systemic sclerosis: a critical digest of the recent literature. Clin Exp Rheumatol 2014; 32: 194-205.
29. IHN H: Autocrine TGF-beta signaling in the pathogenesis of systemic sclerosis. J Dermatol Sci 2008; 49: 103-13.
30. BARNES TC, ANDERSON ME, MOOTS RJ et al.: The many faces of interleukin-6: the role of IL-6 in inflammation, vasculopathy, and fibrosis in systemic sclerosis. Int J Rheumatol 2011; 2011: 721608.
31. MOLET S, HAMID Q, DAVOINE F et al.: IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines. J Allergy Clin Immunol 2001; 108: 430-38.
32. NEEDLEMAN BW, WIGLEY FM, STAIR RW: Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor a, and interferon-g levels in sera from patients with scleroderma. Arthritis Rheum 1992; 35: 67-72.
33. NAKAHARA H, SONG J, SUGIMOTO M et al.: Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum 2003; 48: 1521-9.
34. SHIMA Y, KUWAHARA Y, MUROTA H et al.: The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology (Oxford) 2010; 49: 2408-12.
35. LIU T, HU XD: Transdifferentiation of fibroblasts into myofibroblasts in the skin lesion of systemic sclerosis: role of transforming growth factor β1 and its signal transduction. Nan Fang Yi Ke Da Xue Xue Bao 2011; 31: 1840-5.